Oncology Central

AACR 2018 lung cancer advancements: how will the findings translate in clinic?

At the American Association for Cancer Research Annual Meeting 2018 (April 14–18, IL, USA),back-to-back presentations highlighted the advances in immunotherapy treatments for lung cancer, the deadliest cancer worldwide with approximately 1.7 million deaths per year [1]. Researchers from across the globe presented their published anti-PD-1/anti-PD-L1 trials and the results will change the way some lung cancers are approached.

The treatments:

  • Pembrolizumab (Keytruda ®) plus chemotherapy fared significantly better than chemotherapy alone in nonsquamous Non-Small Cell Lung Cancer (NSCLC) in the Keynote-189 trial, as published in The New England Journal of Medicine 
  • Nivolumab (Opdivo ®) plus ipilimumab (Yervoy ®) had significantly higher progression-free survival than NSCLC patients treated with chemotherapy when they had a high Tumor Mutational Burden (TMB > 10 mutations/Mb) in the CheckMate-227 trial, also published in The New England Journal of Medicine
  • Atezolizumab (Tecentriq®) plus bevacizumab (Avastin®) and chemotherapy showed an improvement in progression-free survival over bevacizumab and chemotherapy in the IMpower150 trial of nonsquamous NSCLC patients
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.